To explore the clinical consequences and potential root causes of insulin pump-associated adverse events (AEs) reported in the Food and Drug Administration's Manufacturer and User Facility Device Experience (MAUDE) database.
Research Design and Methods:
Qualitative template analysis of narrative data in a 20% stratified random sample (n = 2429) of reported AEs that occurred during the first 6 months of 2020 involving five insulin pump models marketed at that time: (1) MiniMed™ 670G, (2) MiniMed™ 630G, (3) Omnipod®, (4) Omnipod DASH®, and (5) t:slim X2™.
Results:
Of the 2429 AEs, 92% included a clinical consequence in the narrative description, with critical hyperglycemia (i.e., blood glucose [BG] >400 mg/dL; 47%) and critical hypoglycemia (i.e., BG <54 mg/dL; 24%) being the most common consequence cited. Only 50% of the AE narratives included information to support the identification of a root cause. The most cited root cause informing remarks were issues with the pump or pod reservoir/cartridge (9%), the occurrence of an obstruction of flow alarm (8%), and problems with the infusion set or site (8%). Some clinical consequences and root cause informing remarks were cited more frequently in AE narratives involving specific insulin pump models, but manufacturer variability in the amount and type of information reported may have affected these findings.
Conclusions:
Our findings show general themes found in insulin pump-associated AE that providers can use to raise patient awareness of potential risks associated with insulin pump use and develop strategies to prevent future AEs. Improvements in AE investigation and reporting processes are still necessary.
Get full access to this article
View all access options for this article.
References
1.
PalaL, DicembriniI, MannucciE. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: An updated meta-analysis of randomized clinical trials. Acta Diabetol, 2019; 56(9):973–980; doi: 10.1007/s00592-019-01326-5
2.
VigerskyRA, HuangS, CorderoTL, et al.Improved HbA1C, total daily insulin dose, and treatment satisfaction with insulin pump therapy compared to multiple daily injections in patients with type 2 diabetes irrespective of baseline c-peptide levels. Endocr Pract, 2018; 24(5):446–452; doi: 10.4158/EP-2017-0234
3.
Cardona-HernandezR, SchwandtA, AlkandariH, et al.Glycemic outcome associated with insulin pump and glucose sensor use in children and adolescents with type 1 diabetes. Data from the international pediatric registry SWEET. Diabetes Care, 2021; 44(5):1176–1184; doi: 10.2337/dc20-1674
4.
FosterNC, BeckRW, MillerKM, et al.State of type 1 diabetes management and outcomes from the T1D exchange in 2016–2018. Diabetes Technol Ther, 2019; 21(2):66–72; doi: 10.1089/dia.2018.0384
5.
ChlupR, RunzisS, CastanedaJ, et al.Complex assessment of metabolic effectiveness of insulin pump therapy in patients with type 2 diabetes beyond HbA1c reduction. Diabetes Technol Ther, 2018; 20(2):153–159; doi: 10.1089/dia.2017.0283
6.
ReznikY, CohenO, AronsonR, et al.Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): A randomised open-label controlled trial. Lancet, 2014; 384(9950):1265–1272; doi: 10.1016/S0140-6736(14)61037-0
7.
AronsonR, ReznikY, CongetI, et al.Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12-month data from the OpT2mise randomized trial. Diabetes Obes Metab, 2016; 18(5):500–507; doi: 10.1111/dom.12642
8.
ZippR. Medtech Dive. Insulin pump adoption seen climbing 21% in 2021 on wearables boom: Survey. Washington, DC; 2021. Available from: https://www.medtechdive.com/news/insulin-pump-adoption-seen-climbing-21-in-2021-on-wearables-boom-survey/596207/#:∼:text=Adoption%20among%20insulin%2Dintensive%20Type,2%20market%20at%20%242%20billion [Last accessed: November 7, 2022].
9.
RossPL, MilburnJ, ReithDM, et al.Clinical review: Insulin pump-associated adverse events in adults and children. Acta Diabetol, 2015; 52(6):1017–1024; doi: 10.1007/s00592-015-0784-2
10.
MohrH, WeissM. Associated Press. Insulin pumps have most reported problems in FDA database. New York, NY; 2018. Available from: https://apnews.com/article/north-america-diabetes-us-news-ap-top-news-health-2f782225f9d74bb9941933b12f8e96f6#:∼:text=Collectively%2C%20insulin%20pumps%20and%20their,analysis%20of%20reports%20since%202008 [Last accessed: November 7, 2022].
11.
KrouwerJS.Adverse event data for years 2018 to 2020 for diabetes devices. J Diabetes Sci Technol, 2022; 16(5):1299–1302; doi: 10.1177/19322968211011688
12.
WheelerBJ, HeelsK, DonaghueKC, et al.Insulin pump-associated adverse events in children and adolescents—A prospective study. Diabetes Technol Ther, 2014; 16(9):558–562; doi: 10.1089/dia.2013.0388
13.
WheelerBJ, DonaghueKC, HeelsK, et al.Family perceptions of insulin pump adverse events in children and adolescents. Diabetes Technol Ther, 2014; 16(4):204–207; doi: 10.1089/dia.2013.0315
14.
GiessmannLC, KannPH. Risk and relevance of insulin pump therapy in the aetiology of ketoacidosis in people with type 1 diabetes. Exp Clin Endocrinol Diabetes, 2020; 128(11):745–751; doi: 10.1055/a-0654-5134
15.
JackmanJ, ChafeR, AlbrechtsonsD, et al.Delayed diagnosis and issues with pump usage are the leading causes of diabetic ketoacidosis in children with diabetes living in Newfoundland and Labrador, Canada. BMC Res Notes, 2015; 8:158; doi: 10.1186/s13104-015-1115-y
16.
EverettEM, CopelandTP, MoinT, et al.Insulin pump-related inpatient admissions in a national sample of youth with type 1 diabetes. J Clin Endocrinol Metab, 2022; 107(6):e2381–e2387; doi: 10.1210/clinem/dgac047
17.
KjærulffMLBG, AstrupBS. Sudden death due to diabetic ketoacidosis following power failure of an insulin pump: Autopsy and pump data. J Forensic Leg Med, 2019; 63:34–39; doi: 10.1016/j.jflm.2019.02.013
18.
PickupJC, YemaneN, BrackenridgeA, et al.Nonmetabolic complications of continuous subcutaneous insulin infusion: A patient survey. Diabetes Technol Ther, 2014; 16(3):145–149; doi: 10.1089/dia.2013.0192
19.
NevesALD, MartinsLEG, GabbayMAL, et al.Insulin pump-associated adverse events in a Brazilian reference center for the treatment of diabetes mellitus: proposal for a taxonomy of device failures in adults, adolescents, and children. J Diabetes Sci Technol, 2022;19322968221106196. [Epub ahead of print]; doi: 10.1177/19322968221106196
20.
TalebN, MessierV, Ott-BraschiS, et al.Perceptions and experiences of adult patients with type 1 diabetes using continuous subcutaneous insulin infusion therapy: Results of an online survey. Diabetes Res Clin Pract, 2018; 144:42–50; doi: 10.1016/j.diabres.2018.07.035
21.
HeinemannL, FlemingGA, PetrieJR, et al.Insulin pump risks and benefits: A clinical appraisal of pump safety standards, adverse event reporting and research needs. A joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetologia, 2015; 58(5):862–870; doi: 10.1007/s00125-015-3513-z
22.
U.S. Food and Drug Administration. Manufacturer and User Facility Device Experience (MAUDE) database. Silver Spring, MD; 1991–2022. Available from: www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm [Last accessed: November 7, 2022].
23.
KingN. Template Analysis. In: Qualitative Methods and Analysis in Organisational Research: A Practical Guide. (Symon G, Cassell C. eds.) SAGE Publications, Inc.; London; 1998; pp. 118–134.
24.
KingN. Using Templates in the Thematic Analysis of Text. In: Essential Guide to Qualitative Methods in Organizational Research. (Cassell C, Symon G. eds.). SAGE Publications, Inc.; London; 2004; pp. 256–270.
25.
SaundersB, SimJ, KingstoneT, et al.Saturation in qualitative research: Exploring its conceptualization and operationalization. Qual Quant, 2018; 52(4):1893–1907; doi: 10.1007/s11135-017-0574-8
26.
GarrisonDR, Cleveland-InnesM, KooleM, et al.Revisiting methodological issues in transcript analysis: Negotiated coding and reliability. Internet High Educ, 2006; 9(1):1–8.
27.
American Diabetes Association Professional PracticeCommittee, DrazninB, ArodaVR, et al.Glycemic targets: Standards of medical care in diabetes-2022. Diabetes Care, 2022; 45(Suppl 1):S83–S96; doi: 10.2337/dc22-S006
28.
BergenstalRM, AhmannAJ, BaileyT, et al.Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: The Ambulatory Glucose Profile (AGP). Diabetes Technol Ther, 2013; 15(3):198–211; doi: 10.1089/dia.2013.0051
29.
LevinsonDR. U.S. Department of Health and Human Services' Office of Inspector General. Adverse Events in Hospitals: National Incidence Among Medicare Beneficiaries. Washington, DC; 2010. Available from: http://oig.hhs.gov/oei/reports/oei-06-09-00090.pdf [Last accessed: November 7, 2022].
30.
KaldjianLC, JonesEW, WuBJ, et al.Reporting medical errors to improve patient safety: A survey of physicians in teaching hospitals. Arch Intern Med, 2008; 168(1):40–46; doi: 10.1001/archinternmed.2007.12
31.
FuchsJ, HovorkaR. Closed-loop control in insulin pumps for type-1 diabetes mellitus: Safety and efficacy. Expert Rev Med Devices, 2020; 17(7):707–720; doi: 10.1080/17434440.2020.1784724
32.
GurtcheffSE.Introduction to the MAUDE database. Clin Obstet Gynecol, 2008; 51(1):120–123; doi: 10.1097/GRF.0b013e318161e657
33.
Department of Veterans Affairs National Center for Patient Safety. Guide to Performing a Root Cause Analysis. Ann Arbor, MI; 2021. Available from: RCA-Guidebook_02052021.pdf(va.gov) [Last accessed: November 7, 2022].
34.
HagleyG, MillsPD, WattsBV, et al.Review of alternatives to root cause analysis: Developing a robust system for incident report analysis. BMJ Open Qual, 2019; 8(3):e000646; doi: 10.1136/bmjoq-2019-000646
35.
MesserLH, BergetC, VigersT, et al.Real world hybrid closed-loop discontinuation: Predictors and perceptions of youth discontinuing the 670G system in the first 6 months. Pediatr Diabetes, 2020; 21(2):319–327; doi: 10.1111/pedi.12971
36.
KrouwerJS.An Analysis of 2019 FDA adverse events for two insulin pumps and two continuous glucose monitors. J Diabetes Sci Technol, 2022; 16(1):228–232; doi: 10.1177/1932296820951872
37.
FauldsER, WyneKL, BuschurEO, et al.Insulin pump malfunction during hospitalization: Two case reports. Diabetes Technol Ther, 2016; 18(6):399–403; doi: 10.1089/dia.2015.0434
38.
KavanaghKT, BrownREJr., KramanSS, et al.Reporter's occupation and source of adverse device event reports contained in the FDA's MAUDE database. Patient Relat Outcome Meas, 2019; 10:205–208; doi: 10.2147/PROM.S212991
39.
U.S. Food and Drug Administration. Medtronic recalls MiniMed insulin pumps for incorrect insulin dosing. Available from: https://www.fda.gov/medical-devices/medical-device-recalls/medtronic-recalls-minimed-insulin-pumps-incorrect-insulin-dosing [Last accessed: January 4, 2023].
40.
U.S. Food and Drug Administration. Insulet Recalls Omnipod DASH Insulin Management System's Personal Diabetes Manager (PDM) for Risk of Battery Swelling, Leakage, or Extreme Overheating. Available from: https://www.fda.gov/medical-devices/medical-device-recalls/insulet-recalls-omnipod-dash-insulin-management-systems-personal-diabetes-manager-pdm-risk-battery [Last accessed: January 4, 2023].
41.
U.S. Food and Drug Administration. Class 2 Device Recall t:slim X2 Insulin Pump with Dexcom G5 Mobile CGM and t:slim X2 Insulin Pump with BasalIQ Technology. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=193503 [Last accessed: January 4, 2023].
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
